Ernexa Therapeutics Inc 8-K, filed Nov 23, 2022
Ernexa Therapeutics Inc. (ERNA)
8-K
2022-11-23
For: 2022-11-22
View Original
Added on
April 06, 2026
About this 8-K
Ernexa Therapeutics Inc filed this 8-K on November 23, 2022, reporting on events of November 22, 2022.
Items reported
- Item 3.01: Delisting notice or listing transfer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 22, 2022
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
||
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212 ) 582-1199
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities
Exchange Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On November 22, 2022, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s stockholders’ equity of approximately $8.8 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022,
fails to comply with the minimum $10.0 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(1)(A) (the “Nasdaq Listing Rule”).
The Notice has no immediate effect on the listing of the
Company’s common stock, par value $0.005 per share (“Common Stock”) on Nasdaq.
However, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, then the Common Stock will be subject to delisting from Nasdaq. As set forth in the Notice, the Company has 45 days to submit a plan to Nasdaq to regain
compliance with the Nasdaq Listing Rule, and, if such plan is accepted, Nasdaq can grant the Company an extension of up to 180 calendar days from the date of the Notice to regain compliance. If the Company timely submits a plan, but Nasdaq does not
accept such plan, then the Company will have an opportunity to appeal that decision to a Nasdaq hearings panel. The Notice further provides that the Company may also consider applying to transfer the Common Stock to The Nasdaq Capital Market,
subject to the Company submitting an online transfer application, paying the requisite fee and satisfying such market’s continued listing requirements.
The Company currently intends to submit a plan with respect to regaining compliance with the Nasdaq Listing Rule;
however, the Company may also pursue a transfer of its listing from the Nasdaq Global Market to the Nasdaq Capital Market.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
|
Eterna Therapeutics Inc.
|
||
|
Dated: November 23, 2022
|
By:
|
/s/ Andrew Jackson
|
|
Andrew Jackson
|
||
|
Chief Financial Officer
|
||